SCHEMBL6533038

SCHEMBL6533038

O=C(Nc1ccccc1F)C(=O)c1cn(Cc2cccnc2)c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
CNR2 P34972 2/20 0.57
CNR1 P21554 1/20 0.57
TUBB4A P04350 1/20 0.55
TUBB P07437 1/20 0.55
TUBA3C P0DPH7 1/20 0.55
TUBA1B P68363 1/20 0.55
TUBA4A P68366 1/20 0.55
TUBB4B P68371 1/20 0.55
TUBB3 Q13509 1/20 0.55
TUBB2A Q13885 1/20 0.55
TUBB8 Q3ZCM7 1/20 0.55
TUBA3E Q6PEY2 1/20 0.55
TUBA1A Q71U36 1/20 0.55
TUBA1C Q9BQE3 1/20 0.55
TUBB6 Q9BUF5 1/20 0.55
TUBB2B Q9BVA1 1/20 0.55
TUBB1 Q9H4B7 1/20 0.55
HTT P42858 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848175 0.86 TUBB4A (0.63) MAPTSMN1; SMN2CNR2CNR1TUBB4A
SCHEMBL3845507 0.85 TUBB4A (0.76) MAPTCNR2CNR1TUBB4ATUBB
SCHEMBL3854264 0.81 TUBB4A (0.67) MAPTSMN1; SMN2CNR2CNR1TUBB4A
SCHEMBL3845826 0.80 TUBB4A (0.66) MAPTSMN1; SMN2CNR2CNR1TUBB4A
SCHEMBL13013313 0.79 CNR2 (0.66) CNR2CNR1TUBB4ATUBBTUBA3C
SCHEMBL28579237 0.78 SLC22A12 (0.68) MAPTSMN1; SMN2CNR2CNR1HTT
SCHEMBL4019994 0.77 PDE4A (0.61) MAPTSMN1; SMN2CNR2TUBB4ATUBB
SCHEMBL3166384 0.76 TUBB4A (0.85) MAPTSMN1; SMN2CNR2CNR1TUBB4A
SCHEMBL6093650 0.75 TUBB4A (0.59) MAPTSMN1; SMN2CNR2CNR1TUBB4A
SCHEMBL28584060 0.75 KDM4E (0.62) MAPTSMN1; SMN2CNR2CNR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919344-B2 N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action ASTA MEDICA, AKTIENGESELLSCHAFT (DE) 2005-07-19 US disclosed
US-20020161025-A1 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action ZIOPHARM ONCOLOGY, INC. 2002-10-31 US disclosed
US-6344467-B1 ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNOMODULATING PROPERTIES ASTA MEDICA AG (DE) 2002-02-05 US disclosed
US-6008231-A ANTIALLERGENS, ANTIHISTAMINES, IMMUNOSUPPRESSANTS, IMMUNOMODULATORS ASTA MEDICA AKTIENGESELLSCHGT (DE) 1999-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161025-A1 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action IDO1, IDO2, INMT MAPT 3626/4885SMN1; SMN2 4851/4885CNR2 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.